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ABSTRACT
Accomplishments and contributions in a career in ra-
diation oncology, and in medicine in general, involve
individual choices that impact the direction of a spe-
cialty, decisions in patient care, consequences of
treatment outcome, and personal satisfaction. Issues
in radiation oncology include: the development and
implementation of new radiation treatment technol-
ogy; the use of multimodality and biologically based
therapies; the role of nonradiation “energy” technol-
ogies,oftenbyothermedicalspecialties,includingthe
need for quality assurance in treatment and data re-
porting;andthetypeofevidence,includingappropri-
ate study design, analysis, and rigorous long-term
follow-up, that is sought before widespread imple-
mentation of a new treatment. Personal choices must
weigh: the pressure from institutions—practices, de-
partments, universities, and hospitals; the need to
serve society and the underserved; the balance be-
tween individual reward and a greater mission; and
thecriticalroleofpersonalvaluesandintegrity,often
requiring difficult and “life-defining” decisions. The
impact that each of us makes in a career is perhaps
more a result of character than of the specific details
enumerated on one’s curriculum vitae. The individ-
ualtapestryweavedbychoosingthemoreorlesstrav-
eled paths during a career results in many pathways
that would be called success; however, the one path
for which there is no good alternative is that of living
and acting with integrity. The Oncologist 2010;15:
332–337
The Road Not Taken
—Robert Frost, 1874–1963
Two roads diverged in a yellow wood
And sorry I could not travel both
And be one traveler, long I stood
And looked down one as far as I could
To where it bent in the undergrowth;
Then took the other, as just as fair,
And having perhaps the better claim,
Because it was grassy and wanted wear;
Though as for that the passing there
Had worn them really about the same,
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In leaves no step had trodden black.
Oh, I kept the first for another day!
Yet knowing how way leads on to way,
I doubted if I should ever come back.
I shall be telling this with a sigh
Somewhere ages and ages hence:
Two roads diverged in a wood, and I—
I took the one less traveled by,
And that has made all the difference
INTRODUCTION
The occasion of this translational research conference in-
cluded the celebration of one of the author’s (E.G.) 70th
birthday and a tour of the new University of Pennsylvania
proton treatment facility in the Perelman Center for Ad-
vanced Medicine. The American Society for Radiation On-
cology(ASTRO)alsocelebratedits50thbirthdaythisyear,
so this is a good time to think of where we—as individuals
andastheradiationoncologyaggregate—areandwherewe
aregoingintheworldofmedicine.Medicineingeneraland
oncology in particular are facing historic opportunities and
challenges with molecular and personalized medicine, a
wealth of new technologies for imaging and treatment,
health care costs rising in the face of a struggling economy,
andmanypeopleintheU.S.whoareun-orunderinsuredon
topofthemanypeopleworldwidelivingwithminimaltono
effective cancer care. The Robert Frost poem above pro-
videsathoughtfulframeworkwithwhichtolookbackatthe
five decades of radiation oncology and consider how one’s
choicesanddecisionsinfluencehowacareerispursuedand
how a professional life is lived.
Whichroaddoesonechoose?Theonemoreorlesstrav-
eled? Is it possible to travel both of them, at least in part?
How will lessons learned on one be applied farther down
the road? Is the “sigh” one of relief or regret for having
taken the road less traveled? And, how does one’s choice
and pursuit of a career “make all the difference”?
In this paper we consider career paths and choices for
our specialty that we (C.N.C. and E.G.) have seen and ex-
perienced using examples from segments of our careers in
commonatStanfordUniversityandtheNationalCancerIn-
stitute, and from 35 years of being colleagues in radiation
oncology. There are, of course, many examples one could
use and no doubt each reader will have their own experi-
ences to consider.
In Figure 1, The paths we choose. . . , there are three
sets of paths for radiation oncology: (a) radiation and
systemic therapy, including chemotherapy and biologi-
cal-based therapy; (b) technology and clinical science,
includinghowweasafielddecideonwhattechnologyto
use;and(c)motivationandlegacy—whatdrivesourpro-
fessional lives and how decisions now will determine the
view of our careers and contributions when looking back
years or decades hence.
RADIATION AND SYSTEMIC THERAPY (BLACK)
Perhaps surprisingly to most oncologists, it was not so
many years ago that the ability for people to tolerate a tu-
moricidal radiation dose was doubted and, in fact, consid-
ered dangerous! Henry Kaplan, a teacher and mentor to
both of us, demonstrated in Hodgkin’s disease that large
fields could be treated to high doses, and cures were seen in
patients with limited stage disease. His work, and that of
Vera Peters, was a watershed in radiation oncology. Mov-
ing forward with higher doses and bigger fields, however,
radiation was shown to have its limits with more extensive
stages of disease, so that the composite lessons were that
one must achieve the necessary radiation dose to kill both
grossandmicroscopicdiseasebutthebiologyofthedisease
and its propensity to metastasize/spread, probably more
than radiation toxicity, put a limit on very extensive field
radiotherapy.
While still remaining aligned with diagnostic imaging
and nuclear medicine, radiation oncology had become a
separate specialty by the late 1960s, with early leaders fo-
cusing on technology development, patterns of disease
spread, and cellular and tissue radiation biology. Radiation
oncologists administered systemic therapy as well, a prac-
tice still prevalent in many countries. Thus, combined mo-
dality therapy (CMT) arose from radiation oncology, with
the Radiation Therapy Oncology Group (RTOG) doing
someofthegroundbreakingwork.Thespecialtyofmedical
oncology was established about 35 years ago, and medical
and radiation oncology may be viewed variably over the
years as competitive, complementary, and collaborative.
Drs. Kaplan and Rosenberg [1] and Stanford colleagues
studiedhowtooptimizedrugsandradiationtogether.Using
both Hodgkin’s disease and the non-Hodgkin’s lympho-
mas, they conducted a pioneering series of randomized tri-
als that demonstrated the benefits of the optimal use of
radiation in conjunction with combination chemotherapy,
and subsequent studies by many research groups have con-
tinued to refine and tailor Hodgkin’s treatment. Indeed, the
issue for Hodgkin’s disease once was “should treatment be
radiation or CMT?” And now chemotherapy alone has
emerged as a legitimate option. As an example of how an
approach from the past can be relevant in the future, the
“low-dose” radiation approach advocated by the very con-
servativeradiologists50yearsagoisnowakeysupplemen-
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primarily chemotherapy based.
Wherearewenowwithregardtoradiationandsystemic
therapy?
CMT
For most solid tumors, CMT is the only thing that has been
shown to improve the survival time following surgery.
Based on the fast pace of scientific developments and rapid
growthinthearmamentariumofnewagentsandinnovative
radiation therapy fractionation, it is necessary to complete
clinical trials in a timely manner for new knowledge to
reach broad clinical application.
Empiricism Versus “Science”
Translating laboratory findings to the clinic is not an easy
gap to cross and requires that one test, not prove, hypothe-
ses (“Test it, don’t tout it!”—E.G.). What works in the con-
trolled environment of the lab, often with doses and
schedules much different than are useable in patients [2], is
often not successful in the clinic, or ends up working by
very different mechanisms. An example is the epidermal
growth factor receptor (EGFR) inhibitor story, in which the
efficacy of the inhibitor was not a result of EGFR overex-
pression, as initially postulated, but rather a result of spe-
cific EGFR mutations in lung cancer and KRAS mutations
in colon cancer.
Radiation Biology
Classic versus modern is not a correct classification or dis-
tinction.Classicisamisnomerinthatthetoolsandfindings
of “nonmolecular” research are essential to molecular biol-
ogyapplications,withtheword“classic”toooftenusedpe-
joratively. Examples include understanding the effects of
molecular interventions on radiobiology assays of cell sur-
vival, DNA repair, cell cycle perturbation, and drug–radia-
tion interaction.
Although animal models remain to be optimized for tu-
mor-related studies, normal tissue radiation and combined
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Figure 1. The paths we choose. There are numerous choices that have shaped where radiation oncology has been and where it is
going. These involve: (a) radiation and systemic therapy—radiation fields and doses, and radiation modifiers, which include che-
motherapy,immunotherapyandradiationsensitizers,protectors,andpersonalizedmedicine;(b)technologyandclinicalscience—
newtechnologyinvolvingradiation,otherformsofenergy,andtheconductofrigorousclinicaltrialstoassessthenewtreatments;
and (c) motivation and legacy—the professional and personal decisions that define who we are and what we truly accomplish.
Careersareatapestryofthesevariouschoicesandpathways.Inourlongview,onepathhasnogoodalternativeandthatisthepath
of living with integrity.
Abbreviations: 3D, three-dimensional; CMT, combined modality therapy; CNS, central nervous system; HD, Hodgkin’s dis-
ease; IGRT, image-guided radiation therapy; IMRT, intensity-modulated radiation therapy; peds, pediatrics; RT, radiotherapy;
Rx, therapy.
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clinical trials.
Preclinical animal and cell/tissue biology studies are
useful in the design of phase I and phase II CMT trials and
toexaminepotentialbiomarkersforradiationandtreatment
effects.
Radiation and Drugs—Two Sides of the Same
Coin?
Both radiation and drugs produce molecular events, with
radiation being able to focus its effects in time and space
(“focused biology” [3]). By using the local effects of radi-
ation, it may be possible to enhance immunotherapy or the
efficacy of chemotherapy. In that radiation can be physi-
cally targeted, depending on the biological effect desired,
the cumulative radiation dose can be varied by a factor of
100 or more (10 cGy to 1,000 cGy for single-dose therapy
and up to 8,000 cGy with fractionation).
TECHNOLOGY AND CLINICAL SCIENCE (BLUE)
In the second series of paths, we first consider the upper
path of radiation. The requirement to use formal simulation
rather than clinical setups—which was debated not as long
ago as one might imagine—has led to the increasing use of
imaging in radiation therapy. Clinical simulation did re-
quire a thorough understanding of the anatomical spread of
tumors. Computed tomography scanning came on the
scene, allowing the development of three-dimensional con-
formal therapy. Further development of computer technol-
ogy has enabled the development of intensity-modulated
radiation therapy and image-guided radiation therapy. The
abilitytodeliverradiationwithprecisionhasledtoexciting
newpossibilitieswithexternal-beamx-raytherapy,brachy-
therapy, and particle therapy with protons in the U.S. and
also with carbon ions internationally.
Useofotherformsofenergytotreattumorsinthelower
part of the “technology and clinical science” pathway has
beenavailableforthreedecades,startingwithhyperthermia
and now involving focused ultrasound, radiofrequency ab-
lation, photodynamic therapy, and cryotherapy. An overar-
ching theme has been the discordance between the picture
of a treatment (isodose, isotherm, isoenergetic line) on a
computerscreenandtheabilitytoactuallydeliverthattreat-
ment. All modalities are limited by target definition and by
the limits of the physics and biology of imaging. Radiation
is limited by inter- and intrafraction motion; hyperthermia
andfocusedultrasoundarelimitedbytissueboundariesand
tissue heterogeneity and by the ability of the body to dissi-
pate heat; and cryotherapy is limited by the ability to define
the boundary of the tumor and the actual physical ablation
of normal tissue that is produced. These energy modalities
are occasionally used in combination, and more and more
one modality is used to salvage failure by another.
Key lessons learned and learned again with these other
energies are: (a) the need to define and standardize the pa-
rameters of the treatment, including the dose delivery and
margin; (b) that isodoses are different for radiation than for
other forms of energy that are dissipated physiologically;
(c)theimportanceoffastidiousqualityassurancesoatreat-
ment in one facility can be related to treatment in another
(or even another treatment in the same facility); and (d) the
need for some skepticism in interpreting tumor location
based on imaging. Radiation oncology has been a leader in
setting standards for the clinical use of complex technol-
ogy, including the RTOG, Quality Assurance Review Cen-
ter [4], and Advanced Technology Consortium [5]. It is
imperative that those using other forms of energy make the
effort to develop and apply standards of treatment delivery
and quality assurance as is done in radiation oncology.
How do physicians choose what they recommend for
treatment to patients under their care (lower blue path in
Fig. 1)? Perhaps one of the most challenging arguments to
overcome is the acceptance of a condition of equipoise so
that clinical trials are conducted before a treatment is
adapted [6]. Patients are not entered in clinical trials for a
variety of reasons, often eligibility criteria; however, there
arethosewhoarguethatequipoiseishard(orimpossible)to
achieve in that the physician always “knows best.” Follow-
ing that logic, randomized clinical trials are not appropriate
orareevenunethical.Afewrecentexamples[7]ofrandom-
ized trials for which there was considerable physician dis-
approval and “conventional wisdom” bias/preference for
one of the treatment arms, but which turned out to not sup-
port the preference, include bone marrow transplantation
for advanced breast cancer, the general use of erythropoie-
tin in cancer patients with anemia, and the use of endovas-
cular brachytherapy for preventing coronary artery
restenosis.
For radiation oncology, the ongoing debate as to the ne-
cessity for conducting randomized trials to determine the
appropriateuseofprotontherapy[8]isanexampleinwhich
the attractive theoretical advantage (isodose on a computer
screen) is a persuasive argument to some that the newer
treatment is better. (Similar arguments are made for other
novel radiation technologies.) Such isodose pictures do not
capture concepts such as integral dose, target motion, and
“marginal miss,” or the risk for radiation-induced injury or
malignancy.Oftensingle-armandregistrytrialsaredonein
place of a randomized trial, which might be the only option
for rare diseases. So, at the end of the lower path in the blue
section, the question may arise as to whether the purpose of
the trial is to “prove” a point or test a hypothesis. Science
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A series of observations that support a preference may be
interesting but are by no means proof. It seems wisest to
take on the hard questions in a proper trial before wide-
spread and possibly inappropriate implementation, and to
use sensible and clinically meaningful criteria for success.
A p-value alone may make a trial statistically significant,
butthechangeintreatmentindicatedbythetrialneedstobe
an important benefit to the patient. There are a number of
recent examples of U.S. Food and Drug Administration
drug approvals for differences in survival of only a few
weeks [9] that have raised this issue of a statistically versus
clinically meaningful result—even more concerning if the
treatment comes with toxicity and great expense.
MOTIVATION AND MISSION (RED)
ThefinalpathinFigure1defineswhoandwhatweare.We
all work for some organization or other and there are pres-
sures to meet the goals of the institution—financial, aca-
demic, practice building, market share—that may come in
conflict with what is best for the patient. The institution
may serve only a sector of society, a decision that may be
determined by the demographics but also by purposeful de-
cisions of what care to provide for the underinsured. The
growingnumberofun-andunderinsured(healthdisparities
populations) will place additional financial burden on insti-
tutions and may bring a physician in conflict with a moral
obligation of service.
We all seek and need some measure of personal reward.
There are the tough decisions as to what one does for one’s
ownneeds—financial,family,fame—andwhatonedoesin
the service of others. Service and mission do not preclude
personal benefit. From our years of observation and expe-
rience, we believe that mission to society is far more re-
warding than self-interest in both the short and long term.
Opportunities for service activities as part of a career are
limited, and time spent in truly altruistic endeavors may
even be detrimental to an academic career, sad to say.
To help provide opportunities for societal contribution,
the Radiation Research Program at the National Cancer In-
stitute (NCI) has helped develop: (a) the Cancer Disparities
Research Partnership program [10], to provide opportuni-
ties for the underserved to participate in NCI clinical trials;
(b) programs with the Office of the Assistant Secretary for
PreparednessandResponse,forradiationexpertstoworkin
terrorism and mass casualty preparedness for the country
andtheircommunity[11];and(c)theCancerExpertCorps,
a peace corps for cancer [12], which is being launched and,
if successful, will provide an opportunity for experts to
mentorthoseworkinginunderservedareasworldwide.The
goal is to raise financial support for people’s time in a man-
ner analogous to a research contract or grant so that this
mentoringandaltruismisapredictableandsustainablepart
of a career and not an add-on during vacations. It would en-
able the establishment of important person-to-person rela-
tionships and a growing network of centers that could
conduct protocol-based care and research worldwide,
thereby bringing excellent stage- and resource-appropriate
care to those who have little to no care available to them.
The final issue of this mission and motivation section is
“what does define ‘me’?” Although having tangible re-
wards and recognition are of value, in our unabashed opin-
ion,whatismostimportantischaracter.TherecentASTRO
50th birthday celebration [13] was an excellent reminder of
how it is the character of the leadership that we remember
more than the specific contributions. The three initial gold
medal winners are outstanding examples: Drs. DelRegato,
Fletcher, and Kaplan. Although our individual accomplish-
ments have an impact, as time goes by, it is our character
and how we go about our daily life that defines each and
every one of us [14].
Up to now on “the paths we choose…” one could pos-
sibly take one path or the other, even wandering back to the
path left behind. Paths part but again intersect and one can
weave one’s own tapestry of interests and pursuits in the
course of a career. At times, the path less traveled may be
preferable (e.g., doing the rigorous studies before introduc-
inganewtreatmentas“standard”)andattimesthepathless
traveled may not be preferable (e.g., jumping on a band-
wagon for an as yet unproven treatment in order to gain
marketshare).Whatdriveseachandeveryoneofustotruly
make the best choice is based on individual character that
on occasion leads us to decisions beyond the path of least
resistance or one of group-think. It is at this last junction on
this diagram that there is but one successful choice. Inter-
estingly, the decision to live and act with integrity or not
maycomeupwhenitisleastexpected.Itmaybeinavisible
situation during the resolution of a major issue or it may be a
quietonewherethechoiceisto:(a)properlyguideapatientfor
their best interest, which may mean sending them elsewhere
for treatment or recommending against treatment; (b) prevent
or at least hamper an institution from doing an immoral or de-
vious action; (c) put principle ahead of profit; or (d) simply
lend a quiet or anonymous hand to a situation in which only
you would notice. Certainly, situations can be ambiguous, al-
thoughoftenrationalizationandabitofself-orgroupdelusion
can obscure doing what is right.
So, the final step in the path is profound. These “life-
definingmoments”notonlydeterminehowyouviewyour-
self and others view you, but they allow you to make the
difference so that when you look back on your path and
336 Choices in Radiation Oncologychoices you will be satisfied and have a good measure of
inner peace that some never seem to obtain.
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